Clinical MedicineUpdated Jul 30, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from JMIR Mental Health indicates that Existing measures of digital TA are often derivatives of traditional TA measures. This is tracked as a clinical because it changes how Digital Therapeutics is understood, validated, or applied. It is supported by 9 papers in the same timeline signal.
Evidence from JMIR Mental Health indicates that BACKGROUND: Tobacco smoking remains the leading cause of preventable death and disease worldwide. This is tracked as a standard because it changes how Digital Therapeutics is understood, validated, or applied.
Evidence from PLoS ONE indicates that Children with ADHD showed enhancements in MFT power, an objective neural measure of attention. This is tracked as a clinical because it changes how Digital Therapeutics is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Frontiers in Digital Health indicates that Meaningful engagement, not just time spent, is crucial for digital therapeutic effectiveness. This is tracked as a standard because it changes how Digital Therapeutics is understood, validated, or applied. It is supported by 4 papers in the same timeline signal.
Evidence from Hypertension Research indicates that Two DTx applications approved and reimbursed in Japan for cardiovascular medicine are detailed. This is tracked as a standard because it changes how Digital Therapeutics is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Australasian Journal of Dermatology indicates that Robust consensus for inclusion of 10 specific labelling items. This is tracked as a standard because it changes how Digital Therapeutics is understood, validated, or applied.
Evidence from the accepted evidence indicates that The IMDRF's risk-based classification system is crucial for determining SaMD regulatory requirements. This is tracked as a clinical because it changes how Digital Therapeutics is understood, validated, or applied.
Evidence from Ophthalmology indicates that The digital therapeutic group improved amblyopic eye visual acuity by 1.8 lines at 12 weeks. This is tracked as a standard because it changes how Digital Therapeutics is understood, validated, or applied. It is supported by 4 papers in the same timeline signal.
Evidence from JMIR Mental Health indicates that The concept of therapeutic alliance is central to traditional psychotherapy. This is tracked as a review because it changes how Digital Therapeutics is understood, validated, or applied.
Evidence from Journal of Medical Internet Research indicates that 85 factors impacting DTx uptake were identified and grouped into 5 categories: policy/system, patient characteristics, DTx properties, health professional characteristics, and outcomes. This is tracked as a clinical because it changes how Digital Therapeutics is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from DIGITAL HEALTH indicates that Individuals with mental health difficulties can form an alliance with mental health apps. This is tracked as a method because it changes how Digital Therapeutics is understood, validated, or applied.
Evidence from DIGITAL HEALTH indicates that Deprexis (depression) and Velibra (anxiety) were the only DTx assessed by multiple countries. This is tracked as a review because it changes how Digital Therapeutics is understood, validated, or applied.